Uncategorized

A PureTech startup banks $180M for a new IPF drug

Published

on

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche’s Esbriet.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version